Understanding MRD and Its Impact on AML Care

What is measurable residual disease (MRD), and why does it matter in AML care? Hematologist-oncologist Dr. Anand Patel explains how this advanced testing can detect tiny amounts of leukemia that may remain after treatment, discusses how MRD testing helps doctors assess remission, and describes the influence of MRD on ongoing AML care and treatment decisions.

Dr. Anand A. Patel is the Medical Director of the Inpatient Leukemia Service at the University of Chicago Medical Center. Learn more about Dr. Patel here: https://www.uchicagomedicine.org/find-a-physician/physician/anand-a-patel.

Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to offer trusted information to empower anyone impacted by cancer, through health equity, health literacy and shared decision-making. Subscribe now to receive the latest news on cancer treatment and research: https://powerfulpatients.org/stay-updated/

Видео Understanding MRD and Its Impact on AML Care канала Patient Empowerment Network